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As children treated for childhood malignancies, rats receiving chemotherapy and their diet matched
controls all showed a significant reduction in growth in weight and height. The rats receiving MTX
or doxorubicin in this study had an additional decrease in tibial length that can not be explained by
redr.rced food intake alone, but must be a side effect of the chemotherapeutic agent itself. Cases of
diarrhea were scarce and it is unlikely that malabsorption was a contributing factor to the growth
retardation in the drug treated rats.
Although growth persists during MTX treatment, the final length is decreased. The effect is less
pronounced than in rats treated with doxorubicin but nevertheless significant.
Cisplatin is well known for its nephrotoxic effect, the accompanying hypomagnesernia affects the
skeleton. It causes cessation of bone growth with a decrease in activity of osteoblasts and osteoclasts,
decreased bone formation and osteopenia.rs':O Cisplatin has a cytotoxic effect on growth plate
chondrocytes in cell cultirres.2a One rvould expect with all these results to see some influence of
cisplatin on length growth. The absence of such an effect in this study can be possibly explained by
the relatively low dose cisplatin.
Malnourished rats have smaller l ivers with a decreased ihydroflolate reductase content. This causes
decreased excretion of methotrexate into bile and increased plasma concentrations and toxicity of the
dmq." ' r rare Doxorubic in is  inact ivatedby g lycosidase,  an enzyme found main ly  in  the l iver  and
kidney.r" Compared to the diet matched controls l iver weight in the doxorubicin treated rats was
increased, this may well be due to parenchymal degeneration and swell ing.5 Decreased liver functron
may increase the serum levels of doxorubicin and the effect of this drug on bone. It is possible that
the additional effects caused by malnutrit ion are the reason we were able to show an effect on length
grorvth of methotrexate and doxorubicin in this study.
In rats treated with cisplatin there was a periodical increase in weight after each dose. Cisplatin is
nephrotoxic and the rveigth increase seen in these rats is due to fluid they accumulate after injection
of the drug. Kidney weight in the cisplatin group was reduced compared to the diet matched controls.
a sign of nephrotoxicicty of cisplatin.
In this experimental rat model, doxorubicin and methotrexate decrease length growth in the rat t ibia
by, respectively I 8 % and 5 o/o, ln contrast cisplatin does not affect length growth at all.
In chapte: four the histological basis of this decrease in length growth is further clarif ied.3l
Histology of the growth plate and metaphysis
' fhe lesults in the ditferent diet control groups in this study were not uniform for every parameter but
it u,as clear that the number of hypertrophic hondrocytes per column rvas increased by malnutrit ion.
Corrrbined with the decreased height ofthis column, this suggested asmaller cell size of the hypertrophic
cells and growth retardation. This is in accordance with the retarded length growth found in these
rats.rr Thr-'effect of malnutrit ion on trabecular volume is not uniform in the different diet control
groups either. The appearance of the metaJ,irlrsis in the different diet control groups does not seem
to differ rnuch from thr. ' ad l ibitum group. L,ong and possibly less well organized trabecula appear.
When lolking at the hist,,rmorphometry results the trabecular bone volume is increased in one diet
94
Summary
control group and decreased in another, making it difficult to drarv a clear conclusion on the effect of
malnutrition on trabecular formation.
Doxorubicitr causes thinning of the growth plate and a disturbed columnar arrangement of
chondrocytes after treatment. Ar8,re column of chondrocytes can be seen as a unit resulting from the
proliferation of one stem cell. The reduced number of cell columns in the doxorubicin treated rats
implies that doxorubicin inhibits stem cell proliferation. A further inhibitive effect on chondrocyte
replication can be deducted from the reduced number ofproliferating chondrocytes. As chondrocytes
are the basis for the formation of trabecula, it is logical that the number of trabecula and trabecular
volume in the doxorubicin treated rats is reduced. Doxorubicin not only inhibits stem cell and
chondrocyte replication which results in growth retardation in these ratsI, bone formation is inhibited
as well. The excess of the fat cells in the marrow could reflect a selective differentiation of stromal
precursor cells down an adipogenic, rather than a osteogenic pathway. This may contribute to the
reduction in trabecular bone volume seen in these animals.
Methotrexate is the one chemotherapeutic agent that is most frequently associated with skeletal
symptoms and side effects.?5 The height of the proliferating layer and the number of proliferating
chondrocytes were not affected by administration of methotrexate. The height of the hypertrophic
layer and the number of cells in it were even increased. The rats treated with methotrexate did
hor.r,ever xhibit growth retardation.3r This is not due to changes in the growth plate itself but a
consequence of the reduction of trabecular volume. The decreased trabecular bone volume may be
due to dinrinished action of osteoblasts as described by some authors 22,t1'3t'1 , an increased recruitment
of osteoclasts as described by othersa or a combination of the two mechanisms.8'r8 In this study bone
ruretabolism parameters were not measured.
Methotrexate is  known to cause myelosuppression in  rats .e The increase in the number of
megakaryocytes in the bone marrow of the rats treated with methotrexate in this study could be
reactive repopulation after cessation of treatment. The last injection of methotrexate was given I
week prior to harvesting of the bones and apparently the bone marrow needs limited time to recover
frorn this dose of MTX.
Cisplatin is associated with nephrotoxicity and known to cause hypomagnesemia.'r Hypomagnesemia
causes cessatior-r of bone growth, thinning of the growth plate with a decrease in activity of osteoblasts
and osteoclasts, decreased bone formation and osteopenia. 35 These effects can be expected when
investigating the effect of cisplatin on the grorvth plate and metaphysis. In this study growth plate
height was not affected by cisplatin, but the height of the proliferating layer was decreased indicating
and inhibit ive effect on cell replication. The increased number of hypertrophic chondrocytes also
indicates a failure ofthese cells to evolve and eventually undergo apoptosis, leading to aretardation
of Iongitudinal growth. Appare,.cly the growth retardation observed in the CDDP rats and their diet
controls are caused by different mechanisms.
Both the appearance of the metaphysis and the histomorphometry results show a decrease in trabecular
volume and bone content caused by CDDP.
Doxorubicin inhibits proliferation of growth plate chondrocytes leading to growth plate thinning
and longitudinal growth retardation. The growth retardation caused by methotrexate is a consequence
of the inhibit ive effect of methotrexate on the trabecular zone. Cell proliferation in the growth plate
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i tself is not inhibited by methotrexate. Cisplatin decreases the height of the proliferating layer of
growth plate chondrocytes, but growth plate height itself is not affected. The trabecular volume of
the proximal t ibial metaphysis is decreased by all three chemotherapeutic agents. Only par-t of the
effect of the chernotherapeutic agents on the growth plate and rnetaphysis can be explained by the
treatment induced m alnutrit ion.
Chapter fbur i l lustrates the complexity of the effects polychemotherapy treatment on the growing
skeleton. In chapter f ive the biontechanical consequences of the histological ef'fects become more
clear.
Biomechanical properties
The resistance of the grorvth plate to shear forces is determined by the intercellular matrix and not by
the chondrocytes.r':r 'ro The weakest area is the zone of hypertrophic hondrocytes. In tlr is layer, the
intercellular matrix content is the lowest.ro With increasing grorvth rate, the growth plate widens,
be'cause of an increase of the hypertrophic zone, and therefore becomes more vulnerable to shear
lbrces. Chernotherapeutic treatment may induce malnutrit ion causing reduced tibial length growth,
rvlt iclr rnay be more pronounced by doxorubicin or methotrexate treatment.rr ln chapter four it was
shown that methotrexate caused an increase in the height of the growth plate, but cisplatin did not
aft-ect it. Doxorubicin was the only chemotherapeutic agent that caused reduction of growth plate
height.rr Under normal circumstances tlr is would increase the she ar strength of the growth plate. The
shear strength ofthe grorvth plate in the current study was reduced by a decreased surface area and
altered nraximurr shear stress. The surface area of the growth plate is decreased in size by the
treatnrent- induced malnr"rtrit ion. In the rats treated with doxorubicin, this was caused by fewer rows
ol'chondrocytes, indicating an inhibit ion of chondrocyte proliferation.12 Why doxorubicin and
nr ethotrexate increase growth plate surface area compared with the malnutrit ioned groups is unclear.
Frorn the altered maximurn shear stress it can be concluded that apparently the quantity or quality of
the rlatrix produced by the grorvth plate chondrocytes is affected. From the results ofthe current
studf it is unclear whether this is caused by a change in organic rnatrix or a change in calcif ication.
Thele is no explanation for the fact that in the diet control group for the rats treated with doxorubicin
the maximum shear stress is increased significantly compared with the ad l ibitum group. Malnutrit ion
in this group seems to increase the rnaximum shear stress of the growth plate, in contrast o the other
diet control groups in which malnutrit ion decreased the maximum shear stress as expected.
Irregularit l,of the growth plate is an additional factor influencing the resistance of the growth plate
to shear fbrces. F ocal clrorrdrocyte necrosis caused by malnutrit ion or chemotherapy could potentially
cxplain some of the results. But the study of serial sections of the growth plate as described in
chapter four shorved this not to be a significant factor.r:
Body r.veight is a significant determinant of bone mineral density and bone strength.{Ekeland,
Engesaeter. et al. I 9 8 I 3 03 /id ) r5 16 Intranr embraneous bone forrnation is respons ible for the w idth
growth of long bones and the increase of cross sectional area. The latter also is influenced positively
by body weight. I ' '  rr Malnutrit ion not only causes growth retardation and a decrease in bone volurne
but also has been shown to aff 'ect the bone mineral content. ri The combination of inrpaired architectural
arrangement of bone and reduction of bone mineral content decreases bone functional strength.rz
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Rats receiving chemotherapeutic treatment feel sick and eat less, resulting in malnutrition and weight
reduction, causing reduction of total femoral and tibial diaphyseal surface area and therefore a
decrease of the maximum bending moment. The altered ratio behveen cortex and medulla, reflected in
the decreased bending resistance, was observed in all groups.
In bone the maximum bending stress of bone increases linearly with increasing bone mineral content.ra
l'he authors may assume that because the maximum bending stress was unaffected in the diet control
groups, the bone mineral content in this study was not decreased by malnutrition. Doxorubicin
clearly affected the geometrical and biomechanical properties of the growing lower limb of the rat.
'fhe 
maximum bending moment needed to break the femur was decreased significantly becuase of a
decreased bending resistance. The bending stress was increased compared with the diet control
group, indicating that bone mineralization was not inhibited by doxorubicin.
As described earlier, methotrexate is known to cause osteopathy in children who are treated with a
long tenn dose for acute lyrnphoblastic leukemia or in children who are treated with a high dose for
osteosarcoma. In chapter five rnethotrexate did not affect the maximum bending strength although
fernoral berrding resistance was decreased. The other factor determining bending strength, (the
maximurn bending stress), did not differ significantly from the diet conhol group.
In chapter five it rvas demonstrated that the maximum bending moment was not affected by cisplatin;
therefore the risk of bone fracture was not increased by this chemotherapeutic agent alone, although
the bending resistance was reduced. Similar to doxorubicin the femoral bending stress was increased
in rats treated with cisplatin, indicating that bone mineralization was not inhibited by cisplatin.
Treatment with doxorubicin, methotrexate, or cisplatin reduces growth plate shear strength, because
of a reduction in surface area and maximum shear stress. These effects are in part explained by the
treatment-induced malnutrition, however the single chemotherapeutic agents also affect the skeleton.
Doxorubicin and cisplatin reduce maximum shear stress of the proximal tibial growth plate suggesting
a change in quantity or quality or both of the intercellular matrix produced by chondrocytes but the
exact rnechanism cannot be determined from these results. Methotrexate has no effect on erowth
plate rnarirnum shear stress.
-freatrnent 
with doxorubicin, rnethotrexate, or cisplatin reduces the diaphysis maximum bending
moment. therfore there is an increased risk of bone fracture. This is caused by a reduction in bending
resistance reflecting the reduced cortex/medulla ratio of the diaphysis. Two factors are responsible
fbr these effects, chemotherapy-induced malnutrition and the accompanying reduction in body
weight and the direct effect of the chemotherapeutic agents on the skeleton. Malnutrition causes a
decrease in maximum bending moment. The exact target of the chemotherapeutic agents within the
bone cannot be determined from the results ofthe current study. Doxorubicin caused a decrease in
bending resistance and bending.noment of the lower l imb. Both methotrexate and cisplatin caused
chanses in geometrical and biomechanical properties of the femur that led to a reduced bending
resistance. A striking finding is that none of the chemotherapeutic agents in this study inhibited
bone rnineralization. Doxorubicin and cisplatin increased the maximum bending stress of the bone,




The I' inal objective of this study was to investigate whether the changes in growth plate and
metaplrvsis morphology and strength resulted in an aberrant fracture pattern after shear loading of
the proximal tibial growth plate. Fracture is easier when the growth plate is \vider r7.37Arthough Salter first
proposed that the fracture l ine in epiphyseal injury invariably runs through the hypertrophic zone,28
it r,vas later shown that more often the pattern of failure after the application of shear forces runs
through different layers of the growth plate.2e.r7 In chapter six it was demonstrated that in healthy
grorving male Wistar rats the pattern of failure in epiphyseal injury runs mainly through the transitional
zone between proliferating and hypertrophic chondrocytes in the growth plate. There are intact
collurnns ofproliferating chondrocytes that are resistant o the shear force and the pattern offailure
may vary throughout the growth plate. This pattern is not altered by treatment induced malnutrition
as can be concluded from the fracture pattern in the diet control groups. Treatment with doxorubicin
does horvever change the pattern offailure after shear loading ofthe growth plate. In the doxorubicin
treated rats the pattern of failure ran largely through the trabecular zone. Hardly any trabecula were
present to resist the shear force causing the fracture. Treatment with doxorubicin weakens the
rnetaphysis in such a way that it appears far less resistant to shear forces than the growth plate itself.
This type of fracture is less favorable. Separation of the epiphysis from the metaphysis and its
vasculature wil l result in growth retardation or cessation and accompanying deformities of the long
bones .
In the methotrexate and cisplatin treated rats the pattern of failure runs through all layers of the
grorvtlr plate and the border with the trabecular area. The metaphysis is less resistant o shear forces
due to the reduced trabecular volume but this does not result in a tl,pe of fracture as seen after
treatrtenl with doxorubicin. Both in the methotrexate and the cisplatin treated rats the hypertrophic
layer ( the rveakest zone in the growth plate) is increased in height and the shear stress ofthe growth
plate is reduced. The latter suggests an altered quantity or quality of the grorvth plate matrix but this
does not result in an altered pattern of failure.
ln conclusion, chapter six shows that doxorubicin affects the pattern of failure after shear loading of
the proxirnal t ibial growth plate. This is due to a reduction in trabecular volume and results in a
fiacture type more prone to healing diff iculties and subsequent grorvth deformities. Methotrexate
and cisplatin do not alter the pattern offailure after epiphyseal injury.
Future perspectives
' l-his 
study provides insight into the etfect of three single chemotherapeutic agents, doxorubicin,
lrethotrexate and cisplatin on the growing skeleton of the rat. Doxorubicin. methotrexate and cisplatin
atfect the grorving rat skeleton in the three areas of most importancel the grorvth plate, metaphysis
and cor tex.  The conch.rs ions ment ioned above are only appl icable to the tested doses of  the
chenrotherapeutic agents and the rat skeleton. The observed effects are short term and it remains
lunclear whether long term ef-fects would be similar. We do horvever f 'eel that these results may
contribute to an explanation for the ever more frequently reported decrease in bone mineral density'
atter completion of chemotherapeutic treatment for childhood cancer. It is clear that not only the
efl-ect of the chemotherapeutic agents themselves, but also treatment induced malnutrit ion exerts an
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important effect on the growing skeleton. All the more reason to be aware of the nutritional state of
the pediatric cancer patient. We feel these results warrant long term follow up of children treated with
cherrrotherapeutic agents, with special attention for skeletal complications.
Close monitoring of length growth and bone mineral density during and after chemotherapeutic
treatment is necessary. In concurrence with the improving survival rates there is a growing number of
reports on decreased bone mineral density after chemotherapeutic treatment for childhood cancer.
We therefore feel it warranted to investigate the possibility and value of the screening of children,
treated with chemotherapeutic agents, at the occurrence of a fracture. Total body magnetic resonance
imaging (lvf Rl) might be the most appropriate diagnostic tool in detecting further (asymptomatic)
skeleta l  abnormal i t ies,  inc luding epiphyseal  in jur ies.6 '36 '2r '23 When chi ldren t reated wi th
chemotherapeutic agents and especially doxorubicin, suffer epiphyseal injury after minor trauma, the
fi-acture pattern may be less favorable. Extra care should be taken to recognize healing deformities
and longer immobilization ma)i be necessary to allow these fractures to heal and to decrease the risk
of grorvth defbrmities. The usefulness of screening for skeletal abnormalit ies and necessity of
suppletion of hormonal factors needs to be investigated. Intervention studies are required to see
rvhether suppletion of vitamin D , phosphate and calcium can prevent an increased morbidity from
liactures not only in the period directly following treatment but also in later life.
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